Video
Preview of ASCO 2022: Dr Everett Vokes
Author(s):
OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Today-
We are reporting from the 2022 ASCO Annual Meeting!
Get ready for highlights of some of the top news presented each day during the meeting—and soon we’ll speak with Dr. Everett Vokes to preview some of the pivotal studies he is most excited about.
Welcome to OncLive® News Network! I’m Caroline Seymour.
In pretreated patients with non–small cell lung cancer harboring a KRAS G12C mutation, treatment with adagrasib was well tolerated and demonstrated promising efficacy. Objective responses were seen in approximately half of patients in the phase 1/2 KRYSTAL-1 trial.
In the phase 3 GEMSTONE-302 trial, the combination of sugemalib and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival versus placebo plus chemotherapy, irrespective of tumor histology or PD-L1 expression levels in patients with newly diagnosed metastatic non–small cell lung cancer.
Data from the phase 1/2 LUPER trial demonstrated preliminary efficacy and a manageable safety profile with treatment with the combination of lurbinectedin and pembrolizumab in patients with relapsed small cell lung cancer.
Finally, results from the ROMAN trial illustrated that avasopasem manganese produced a clinically meaningful improvement in severe oral mucositis versus placebo and was well tolerated in patients with locally advanced, nonmetastatic head and neck cancer.
Please be sure to check out more of our coverage from the 2022 ASCO Annual Meeting at OncLive.com.
That’s all for today. Tomorrow, we’ll virtually sit down with Drs Bradley McGregor and Tanios Bekaii-Saab, who will share their perspectives on breaking research in genitourinary and gastrointestinal cancers.
Thank you for watching OncLive® News Network: On Location, I’m Caroline Seymour.
